VXc-486 (prodrug pVXc-486)

Class: Gyrase B inhibitor

Details of activity:	Active against Mycobacterium tuberculosis, Mycobacterium abscessus, Mycobacterium avium complex, and Mycobacterium kansasii
Description:	Synthetic compound; aminobenzimidazole; active against Mycobacterium tuberculosis within macrophages; prodrug has improved solubility rapidly converted to active compound
Institute where first reported:	Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA
Year first mentioned:	2015
Development status:	Experimental

Chemical structure(s):
Canonical SMILES:	CCNC(=O)NC1=NC2=C([C@H]3CCCO3)C(=C(C=C2N1)C4=CN=C(C(C)(C)O)N=C4)F
Isomeric SMILES:	CCNC(=O)NC1=NC2=C(N1)C=C(C(=C2[C@H]3CCCO3)F)C4=CN=C(N=C4)C(C)(C)O
InChI:	InChI=1S/C21H25FN6O3/c1-4-23-20(29)28-19-26-13-8-12(11-9-24-18(25-10-11)21(2,3)30)16(22)15(17(13)27-19)14-6-5-7-31-14/h8-10,14,30H,4-7H2,1-3H3,(H3,23,26,27,28,29)/t14-/m1/s1
InChI Key:	BKUISYCLLXCBJV-CQSZACIVSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/57524959

External links:
Guide to Pharmacology:	SPR719
Main Source:	https://journals.asm.org/doi/10.1128/aac.04347-14
Citations:	https://pubs.acs.org/doi/10.1021/jm800318d https://journals.asm.org/doi/10.1128/aac.00596-06